Company launches ADC Phase I trial in solid tumours
Drug Discovery World
MARCH 8, 2023
BAT8008 was developed by using Bio-Thera Solutions’ ADC linker-payload that includes a cleavable but systemically stable linker, a small molecule topoisomerase I inhibitor and high DAR. The small molecule topoisomerase I inhibitor payload carried by BAT8008 has a strong cell membrane penetration ability.
Let's personalize your content